U.S. Media Stock News

APA Corporation ( NASDAQ:APA ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...

The latest move in Alvotech (NasdaqGM:ALVO) is being driven by a major regulatory win: European Commission approval of its denosumab biosimilar AVT03, opening the door to a sizeable osteoporosis and oncology market. See our latest analysis for Alvotech. The AVT03 approval has clearly sparked a rebound in sentiment, with a 1 day share price return of 7.89 percent and 30 day share price return of 12.09 percent. However, the 1 year total shareholder return of negative 52.06 percent shows...

Lamb Weston Holdings (LW) has quietly drifted lower this year, even as its earnings and revenue continue to grow. With the stock down about 10% year to date, investors are revisiting its long term case. See our latest analysis for Lamb Weston Holdings. At around a 10% year to date share price decline and a 1 year total shareholder return of roughly negative 21 percent, the stock looks more like a slow bleed than a collapse. Recent setbacks appear to reflect investors reassessing execution...

Victoria's Secret (VSCO) kicked off its latest earnings update with Q2 2026 revenue of about $1.5 billion and basic EPS of $0.20, supported by net income of $16 million and a 4% same store sales uptick that marks a cleaner read on underlying demand. The company has seen quarterly revenue move from $1.35 billion in Q1 2025 to $1.46 billion in Q2 2026, while EPS has swung from a loss of $0.71 in Q3 2025 to the current $0.20. This sets the stage for investors to focus on whether recent margin...

APA (APA) has quietly climbed about 25% over the past month and roughly 19% in the past 3 months, drawing fresh attention to whether the stock still offers value at current levels. See our latest analysis for APA. Zooming out, APA’s recent 1 month share price return of around 25% builds on a solid year to date share price gain, even as the 3 year total shareholder return remains negative. This suggests sentiment has only recently swung back in its favor. If APA’s rebound has you rethinking...

While Akso Health Group ( NASDAQ:AHG ) shareholders are probably generally happy, the stock hasn't had particularly...

If you are wondering whether Par Pacific Holdings is still worth buying after its big run, you are not alone. This article is going to unpack what the current price really implies. The stock has cooled slightly over the last week, down 4.3%, but it is still up 16.1% over 30 days, 161.8% year to date, and 171.9% over the past year. This naturally raises questions about how much upside is left versus how much risk has been priced in. Recent moves have been driven by a mix of refining margin...

Multiple Wall Street firms have recently reiterated or launched Buy ratings on Coterra Energy (CTRA), signaling growing confidence in its multi basin strategy and positioning within a still volatile energy tape. See our latest analysis for Coterra Energy. That upbeat backdrop helps explain why, at a latest share price of $27.39, Coterra has logged a solid 90 day share price return of 14.22 percent and a 1 year total shareholder return of 13.73 percent. This suggests that momentum in the story...

DocuSign (DOCU) just posted Q3 2026 results with revenue of $818.4 million and basic EPS of $0.41, as the company continues to turn its profitability track record from headline to habit. Over the past few quarters, revenue has stepped up from $754.8 million in Q3 2025 to $776.3 million in Q4 2025, then to $763.7 million and $800.6 million in Q1 and Q2 2026, while EPS moved from $0.31 in Q3 2025 to a trailing twelve month figure of $1.49. With that backdrop, investors are watching how much of...

In late November and early December 2025, Kymera Therapeutics highlighted progress for KT-621, its first-in-class oral STAT6 degrader, including completion of the BroADen Phase 1b atopic dermatitis trial and initiation of the BROADEN2 Phase 2b study, while scheduling Phase 1b data release for December 8, 2025. This latest update positions KT-621 at the center of Kymera’s effort to move beyond early proof-of-mechanism and potentially build a multi-indication Type 2 inflammation franchise...

With a median price-to-earnings (or "P/E") ratio of close to 19x in the United States, you could be forgiven for...

At the Barclays Financial Services Conference in September, MarketAxess CEO Chris Concannon and CFO Ilene Fiszel Bieler outlined the company’s evolving growth plan, emphasizing progress in non‑US credit revenue, stronger algorithmic and block trading activity, and plans to deepen integration with ICE Bonds while prioritizing organic growth and selective share repurchases. An interesting takeaway is management’s emphasis on emerging markets, where electronic bond trading remains minimal,...

In recent months, BioMarin Pharmaceutical reported very large year-over-year EPS growth in Q2 2025, highlighted the margin benefits of its 2024 restructuring, and raised guidance for revenue, income, and operating margins while pointing to limited competition for its orphan drug portfolio. Management now expects the full impact of these cost and efficiency measures to emerge in 2026, with promising late-stage trials potentially adding to an already focused rare-disease franchise. Next, we’ll...

To the annoyance of some shareholders, Elutia Inc. ( NASDAQ:ELUT ) shares are down a considerable 28% in the last...

Recent upward revisions to earnings estimates have pushed Fiverr International (FVRR) into the spotlight, as a stronger earnings outlook and favorable ranking are drawing fresh attention from investors watching the freelancing platform. See our latest analysis for Fiverr International. Those upgraded earnings expectations have helped the stock stabilize recently, with a 30 day share price return of 4.8% following a weak year to date share price return of negative 32.8%. This signals improving...

In the third quarter, New York-based Commodore Capital increased its stake in Relay Therapeutics by nearly 3.7 million shares, bringing its holdings to 17 million shares valued at about US$88.70 million, as the company cut expenses and reduced its quarterly net loss while maintaining a cash runway into 2029. Renewed institutional interest appears closely tied to Relay’s advancing clinical programs, particularly RLY-2608 in breast cancer and vascular malformations, which investors may see as...

In late November 2025, QuidelOrtho drew heightened attention after director Joseph D Jr. Wilkins bought 370 shares and CEO Brian J. Blaser purchased 23,500 shares, signaling leadership’s willingness to commit personal capital to the diagnostics company. These insider purchases have become a focal point for investors, who often treat such buying as a real-time indicator of management’s conviction in the company’s prospects. We’ll now examine how this insider buying wave could influence...

If you are wondering whether Constellation Energy at around $359 a share is still worth chasing after a huge multi year run, you are not alone. This is exactly the question we will unpack. The stock has dipped slightly in the last week and month, down about 1.2% over 7 days and 0.9% over 30 days, but it is still up 48.3% year to date and 42.7% over the last year, with a 311.0% gain over 3 years. Those kinds of returns have been associated with rising optimism around US power markets and the...

Smithfield Foods (SFD) has been quietly grinding higher this year, and that steady climb has plenty to do with its improving fundamentals, from modest revenue growth to faster expanding profits. See our latest analysis for Smithfield Foods. At a last close of $21.93, Smithfield’s year to date share price return of 11.04% signals improving sentiment as investors gradually price in its steady earnings momentum rather than chasing short term swings. If this kind of steady compounding appeals to...

The Digital Turbine, Inc. ( NASDAQ:APPS ) share price has softened a substantial 31% over the previous 30 days, handing...

TJX Companies (TJX) just posted another quarter of sales growth while laying out multi billion dollar plans to upgrade stores, distribution, and e commerce. This combination helps explain the stock’s steady climb. See our latest analysis for TJX Companies. That growth story seems to be resonating with investors, with the share price now around $153.28 after a roughly 26.5% year to date share price return and a powerful three year total shareholder return of about 105 percent, helped by steady...

Many EverQuote, Inc. ( NASDAQ:EVER ) insiders ditched their stock over the past year, which may be of interest to the...

Lennar (LEN) has been grinding through a mixed stretch, with the stock slipping over the past 3 months even as revenue edges higher and long term returns remain a focal point for patient investors. See our latest analysis for Lennar. At around $123.91, Lennar’s recent share price pullback, including a weaker 1 week share price return, contrasts with its solid multi year total shareholder returns. This suggests sentiment has cooled even as the long term housing story remains intact. If...

In early December 2025, Business Alliance Financial Services (BAFS) announced it had integrated its BLAST commercial lending platform with Fiserv’s Portico account processing system, giving credit unions using Portico more options to digitize and streamline their commercial loan lifecycles. This integration, alongside Fiserv’s appointment of veteran technology-sector analyst Walter Pritchard as Head of Investor Relations, underscores the company’s emphasis on expanding higher-value software...